Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 212,100
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential ap...
Show more
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617-973-5017
- Address
- 8 Faneuil Hall Marketplace, 3rd Floor, Boston, United States
Latest news
No headlines yet.
